NASDAQ$TECX
Tectonic Therapeutic Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
AVROBIO reported financial results for the fourth quarter and year ended Dec. 31, 2022 and provided a business update.
AVROBIO reported a net loss of $25.0 million for the fourth quarter of 2022. As of Dec. 31, 2022, AVROBIO had $92.6 million in cash and cash equivalents.
- Following positive regulatory feedback, AVROBIO plans to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment
- Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis; plan to initiate late-stage clinical trial activities in second half 2023, subject to regulatory alignment
- Plan to initiate collaborator-sponsored Phase 1/2 clinical trial for mucopolysaccharidosis type II (MPS-II), or Hunter syndrome, in 2023
- AVROBIO expects its cash and cash equivalents as of Dec. 31, 2022, will enable AVROBIO to fund its operating expenses and capital expenditure requirements into the first quarter of 2024.
Headline financials
Revenue & EPS history
Tectonic · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2022
-1.4%
Avg return
Earnings day
-1.0%
Avg return
5 days after
+2.9%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+11.1%
Q4 2021
Best reaction
-20.3%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.4% | +14.5% | +22.6% | |
| Q3 2025 | +1.5% | -0.7% | +4.9% | |
| Q1 2025 | -0.9% | +3.5% | -13.4% | |
| Q4 2024 | +1.0% | -11.8% | +11.0% | |
| Q3 2024 | -2.0% | +6.5% | +14.8% | |
| Q1 2024 | +0.0% | -0.8% | -7.0% | |
| Q4 2023 | +0.8% | -2.3% | -1.6% | |
| Q3 2023 | -9.9% | -13.2% | -7.2% | |
| Q2 2023 | +0.6% | -1.9% | +4.5% | |
| Q1 2023 | -4.5% | -4.5% | +82.1% | |
| Q4 2022 | -20.3% | -14.6% | -23.6% | |
| Q3 2022 | -1.5% | +12.1% | +19.7% | |
| Q2 2022 | +5.0% | +5.9% | -12.9% | |
| Q1 2022 | -7.3% | -1.2% | +30.5% | |
| Q4 2021 | +11.1% | +12.5% | -20.8% | |
| Q3 2021 | -1.0% | -3.8% | -40.7% | |
| Q2 2021 | +6.5% | -17.0% | -13.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro